Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A coagulation disorder characterized by the partial or complete absence of factor V activity in the blood.
No HPO annotations are available for this condition.
Venous thromboembolism (VTE) is the primary clinical manifestation of factor V Leiden thrombophilia . The most common site for VTE is the legs, but upper-extremity, cerebral, and superficial venous thrombosis may also occur. The relative risk for VTE is increased approximately three- to eightfold in factor V Leiden variant heterozygotes . Lower relative risks (four- to fivefold) were reported in two large meta-analyses . Despite the increase in relative risk, the overall annual incidence of a first VTE is low in heterozygotes, approximately 0.5% . The reported adjusted hazard ratio (HR) for VTE in heterozygotes compared with controls was 2.7 (95% confidence interval [CI] 1.8-3.8) .
Factor V Leiden thrombophilia should be suspected in individuals with the following clinical, laboratory, and family history findings:
Clinical findings. A history of one or recurrent venous thromboembolism (VTE) manifesting as deep vein thrombosis (DVT) or pulmonary embolism (PE), especially at a young age and in the absence of strong risk factors for VTE
Laboratory findings. Low activated protein C (APC) resistance on APC resistance qualitative and quantitative assays
No approved treatments are currently available for factor V deficiency. The disease remains an area of unmet medical need.
Gene therapy approaches for factor V deficiency have been reported in the published literature.
To assess the risk for venous thromboembolism (VTE) in an individual found to have a factor V Leiden variant, the following are recommended:
Individuals receiving long-term anticoagulation require periodic reevaluation of their clinical course to confirm that the benefits of anticoagulation continue to outweigh the risk of bleeding. Factor V Leiden heterozygotes who do not require long-term anticoagulation may benefit from evaluation prior to exposure to circumstantial risk factors such as surgery or pregnancy.
Source: GeneReviews — "Factor V Leiden Thrombophilia"
No clinical trials have been registered for factor V deficiency.
47 publications have been identified in PubMed for factor V deficiency. Research spans Case Report / Case Series (62%), Basic Science / Preclinical (15%), and Epidemiology / Natural History (11%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 29 | 62% |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 7:58 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Source: GeneReviews — "Factor V Leiden Thrombophilia"
Source: GeneReviews — "Factor V Leiden Thrombophilia"
The differential diagnosis of venous thromboembolism (VTE) includes several other inherited thrombophilic disorders, including those caused by other variants in F5, and acquired thrombophilic disorders (outside of the scope of this GeneReview). Prothrombin thrombophilia is characterized by VTE manifesting most commonly in adults as deep vein thrombosis (DVT) in the legs or pulmonary embolism. The clinical expression of prothrombin thrombophilia is variable; many individuals heterozygous or homozygous for the 20210GA F2 variant never develop thrombosis, and while most heterozygotes who develop thrombotic complications remain asymptomatic until adulthood, some have recurrent thromboembolism before age 30 years.
Source: GeneReviews — "Factor V Leiden Thrombophilia"
DNA analysis for prothrombin thrombophilia (F2 variant c.*97GA, commonly known as 20210GA)
Multiple phospholipid-dependent coagulation assays for a lupus inhibitor
Serologic assays for anticardiolipin antibodies and anti-beta-2-glycoprotein 1 antibodies
For high-risk individuals (i.e., those with a history of recurrent VTE, especially at a young age, or those with strong family history of VTE at a young age), evaluation should also include assays of:
Protein C activity
Antithrombin activity
Protein S activity or free protein S antigen
Note: Measurement of the following is NOT recommended:
Plasma concentration of homocysteine, as no data support a change in duration of anticoagulation or the use of vitamin supplementation in individuals with hyperhomocysteinemia and a history of VTE
MTHFR variants, as no clinical rationale for this testing exists
Factor VIII and other clotting factor levels
Treatment of Manifestations
The management of individuals with factor V Leiden thrombophilia depends on the clinical circumstances. The first acute thrombosis should be treated according to current guidelines . For initial treatment of VTE, current guidelines suggest a direct oral anticoagulant (dabigatran, edoxaban, rivaroxaban, or apixaban) over warfarin because of a lower bleeding risk and gr...
Source: GeneReviews — "Factor V Leiden Thrombophilia"
View trials for factor V deficiency
7 |
15% |
Disease patterns and progression | 5 | 11% |
Research summaries | 4 | 9% |
Other research | 1 | 2% |
New treatment approaches | 1 | 2% |
Jaine NS (2026). [PMID: 42040680](https://pubmed.ncbi.nlm.nih.gov/42040680/). *Indian J Hematol Blood Transfus*. [Other]
Sasaki Y (2026). [PMID: 42236240](https://pubmed.ncbi.nlm.nih.gov/42236240/). *Rinsho Ketsueki*. [Case Report / Case Series]
Miguel-Batuecas A (2026). [PMID: 41680367](https://pubmed.ncbi.nlm.nih.gov/41680367/). *Scientific reports*. [Review / Meta-Analysis]
Pshenichnikova O (2026). [PMID: 42074284](https://pubmed.ncbi.nlm.nih.gov/42074284/). *Int J Mol Sci*. [Epidemiology / Natural History]
Bamba M (2026). [PMID: 40973613](https://pubmed.ncbi.nlm.nih.gov/40973613/). *Rheumatology (Oxford, England)*. [Case Report / Case Series]
Sugino A (2026). [PMID: 41403788](https://pubmed.ncbi.nlm.nih.gov/41403788/). *IJU case reports*. [Case Report / Case Series]
Yang L (2026). [PMID: 41888913](https://pubmed.ncbi.nlm.nih.gov/41888913/). *Thromb J*. [Case Report / Case Series]
Feng Y (2026). [PMID: 42087734](https://pubmed.ncbi.nlm.nih.gov/42087734/). *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*. [Case Report / Case Series]
Kalantri S (2026). [PMID: 41523906](https://pubmed.ncbi.nlm.nih.gov/41523906/). *Case reports in hematology*. [Case Report / Case Series]
Van Thillo Q (2026). [PMID: 42165251](https://pubmed.ncbi.nlm.nih.gov/42165251/). *Haemophilia*. [Review / Meta-Analysis]
AI-curated news mentioning factor V deficiency
Updated Mar 2, 2026
A recent publication discusses the current management and care gaps for Factor II and Factor V deficiencies, highlighting the need for therapeutic advancements. The article calls for increased research and innovation to improve patient outcomes in these rare bleeding disorders.